FCH
GILD icon

Freestone Capital Holdings’s Gilead Sciences GILD Stock Holding History

Freestone Capital Holdings’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,000
Closed -$72K – 357
2016
Q4 		$72K Buy
+1,000
New +$74.3K 0.01% 342
2016
Q3 		– Sell
-3,500
Closed -$292K – 345
2016
Q2 		$292K Buy
+3,500
New +$311K 0.03% 289

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Freestone Capital Holdings's GILD Position: Q2 2026 in Review

Freestone Capital Holdings increased its Gilead Sciences (GILD) stake by 2.6% in Q2 2026, buying an estimated $29.4K and bringing the position to 8,873 shares worth $1.12M. The position accounts for 0.03% of the portfolio, ranked #243.

Freestone Capital Holdings first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $24.9M in Q3 2018. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Freestone Capital Holdings held 8,873 shares of Gilead Sciences worth $1.12M as of Q2 2026.
  • Freestone Capital Holdings bought 223 Gilead Sciences shares in Q2 2026, an estimated $29.4K.
  • Gilead Sciences made up 0.03% of Freestone Capital Holdings's portfolio in Q2 2026, its #243 holding.
  • Freestone Capital Holdings first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • Freestone Capital Holdings's Gilead Sciences position peaked at $24.9M in Q3 2018.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.